

DISCOVER
DIAGNOSE
DEFEND



Immunohistochemistry (IHC)















IHC in Surgical Pathology

Final Diagnosis Panel

- ▶ Immuno staining of specific antigens in tissues for diagnosis and prognosis
- ▶ Assessment for targeted therapy & monitoring response to therapy
- ▶ Comprehensive review of complex cases/Lymphomas/Metastatic Tumors
- ▶ CAP & WHO approved reporting protocols

India's Leading Super Specialised Laboratory Network

Cancer	IHC Markers
Breast Cancer 	<ul style="list-style-type: none"> • Cathepsin D • Estrogen Receptor(ER) • HMWCK • p53 • Progesterone Receptor (PR) • EGFR (Epidermal Growth Factor Receptor) • E- Cadherin • Her 2 neu • Ki-67 (MIB-1) • p63 • SMA
Lung Cancer 	<ul style="list-style-type: none"> • ALK5F3 on Ventana • Napsin A • p63 • CK5/6 • p40 • TTF-1
Liver Cancer 	<ul style="list-style-type: none"> • Arginase-1 • Glypican-3 • HepPAR-1
Ovarian and Testicular Cancer 	<ul style="list-style-type: none"> • AFP (Alpha Feto Protein) • Inhibin • PLAP (Placental Alkaline Phosphatase) • HCG (Human Chorionic Gonadotropin) • CA-125 • WT1
Thyroid Cancer 	<ul style="list-style-type: none"> • Calcitonin • Thyroglobulin • CK 19 (Cyto Keratin 19) • GFAP (Glial Fibrillary Acidic Protein) • TTF - 1 (Thyroid Transcription Factor - 1)
MSI Marker for Colon Cancer 	<ul style="list-style-type: none"> • MLH1 • MSH6 • MSH2 • PMS2
Prostate Cancer 	<ul style="list-style-type: none"> • AMACR • PSA • HMW CK • p63
Mesothelioma Diagnostic Marker 	<ul style="list-style-type: none"> • Calretinin (Mesothelioma Marker) • HBME - 1 (Mesothelioma Marker) • WT1
Plasma Cell Neoplasm Diagnostic Marker 	<ul style="list-style-type: none"> • CD 19 • CD138 • Kappa • CD56 • MUM-1 • Lambda

Cancer	IHC Markers
<p>Lymphoma Diagnostic/ Prognostic Marker</p> 	<ul style="list-style-type: none"> • BOB-1 • BCL-2 • CD3 • CD4 • CD5, • CD8 • CD7 • CD10 • CD15 • CD19 • CD20 • CD23 • CD30 • CD45 • CD 45 RO • CD57 • CD68 • Cyclin D1 (bcl-1) • Ki-67 • MUM-1 • Oct-02 • Pax-5 • Surface IgM • Kappa Light Chain • Lambda Light Chain • ALK -1 (Anaplastic Lymphoma Kinase -1) • TdT (Terminal deoxynucleotidyl Transferase) • Epithelial Membrane Antigen (EMA)
<p>Undifferentiated Tumor Diagnostic Markers</p> 	<ul style="list-style-type: none"> • CDX-2 • CD56 • Chromogranin A • Desmin • HMB - 45 • MUC-1 • p63 • S100 • WT1 • Synaptophysin • Vimentin • Cytokeratin (Pan Cytokeratin) • NSE (Neuron specific Enolase) • Fli-1 (Ewing's Sarcoma / PNET Marker)
<p>Miscellaneous</p> 	<ul style="list-style-type: none"> • BCL-6 • Calponin • CD1a • CD2 • CD31 • CD34 • CD-43 • CD71 • CD79a • p16 • RCC • CD21 • CD99 (MIC - 2) • DBA44 • CD61 • CK 7 (Cytokeratin 7) • CK8/18 • Pax-8 • Cyclin-D1 • D2-40 • MPO • DOG-1 (GIST Marker) • GCDFFP-15 • Glycophorin A • h- Caldesmon • MOC-31 • Beta Catenin • MUC-2 • MUC5-AC • Myogenin • MyoD1 • UROPLAKIN • Uroplakin-II • CK 20 (Cytokeratin 20) • Annexin-1 (Hairy Cell Leukemia Marker) • CD117 (C-Kit) ~ GIST Marker • CEA (Carcino Embryonic Antigen) • Oct3/4 (Germ Cell Tumor Marker)

Final Diagnosis Panel (FDP) by IHC

- Ideal panel for determination of likely primary site in metastasis of unknown origin.
- Comprehensive organ/site specific set of markers to establish final diagnosis performed by Immunohistochemistry (IHC) technique.
- Establish accurate final diagnosis in poorly differentiated tumors.
- Ideal panel for classification and sub typing of Lymphomas.

Test Details:

Test Name	Specimen	Special Instruction for sample collection	TAT / Reported on
Final Diagnosis Panel (FDP)	<ul style="list-style-type: none"> • Formalin Fixed Paraffin Embedded (FFPE) tissue block/Representative Tissue placed in Formalin sent at room temperature by courier. • Polylysine coated/charged slides are also acceptable (12-15) for FDP • For other panels depending upon the number of markers requested) with an additional H&E slide. • Slides to be transported in proper slide mailers (plastic) with proper labelling. 	<ul style="list-style-type: none"> • Detailed clinical history • Copies of previous relevant cytology/histopathology reports, all relevant radiological investigation reports. • For any FDPs on Bone marrow biopsy specimens, peripheral blood counts, peripheral blood smears and bone marrow aspirate smears are additionally mandatory. • Treating Oncologist/ Surgeon contact details for relevant case discussion are mandatory along with TRF. 	5th Working Day if received before 1300 Hrs.